Suppr超能文献

线粒体 COI/tRNA(Ser(UCN))基因突变在波兰患者中非综合征型和氨基糖苷类诱导性耳聋中的作用。

The contribution of the mitochondrial COI/tRNA(Ser(UCN)) gene mutations to non-syndromic and aminoglycoside-induced hearing loss in Polish patients.

机构信息

Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479 Poznań, Poland.

出版信息

Mol Genet Metab. 2011 Sep-Oct;104(1-2):153-9. doi: 10.1016/j.ymgme.2011.05.004. Epub 2011 May 13.

Abstract

Mutations in mitochondrial DNA have been implicated in both, non-syndromic and aminoglycoside-induced hearing loss. In the present study, we have performed the systematic mutation screening of the COI/tRNA(Ser(UCN)) genes in 250 unrelated Polish subjects with hearing impairment. Three different homoplasmic sequence variants were identified, including one common polymorphism m.7476 C>T in tRNA(Ser(UCN)) and two mutations, m.7444 G>A and m.7445 A>G localized in the COI/precursor of tRNA(Ser(UCN)). The incidence of m.7444 G>A substitution was estimated at 1.6% (4/250), however variable penetrance of hearing loss, age of onset and hearing thresholds among m.7444 G>A carriers was observed. Two subjects had the positive history of aminoglycoside exposure and one of them harbored both m.7444 G>A and 12S rRNA m.1555 A>G mutations. Those suggest that m.7444 G>A itself is not sufficient to produce a clinical phenotype and additional modifier factors are required for pathogenic manifestation of m.7444 G>A substitution. Moreover, we have described the first Polish family with non-syndromic hearing loss, harboring m.7445 A>G mutation. The penetrance of hearing loss in this pedigree was 58% when aminoglycoside-induced hearing impairment was included, and 8% when ototoxic effect was excluded. This finding strongly suggests the possible role of m.7445 A>G in susceptibility to aminoglycoside induced-hearing loss.

摘要

线粒体 DNA 突变与非综合征型和氨基糖苷类诱导的听力损失都有关。在本研究中,我们对 250 名波兰听力障碍无关个体的 COI/tRNA(Ser(UCN)) 基因进行了系统的突变筛查。鉴定出了三种不同的同质序列变体,包括 tRNA(Ser(UCN)) 中的常见多态性 m.7476 C>T 和位于 COI/前体 tRNA(Ser(UCN)) 的 m.7444 G>A 和 m.7445 A>G 两种突变。m.7444 G>A 取代的发生率估计为 1.6%(250 分之 4),但在 m.7444 G>A 携带者中观察到听力损失、发病年龄和听力阈值的可变外显率。有 2 名患者有氨基糖苷类药物暴露的阳性史,其中 1 名患者同时携带 m.7444 G>A 和 12S rRNA m.1555 A>G 突变。这表明 m.7444 G>A 本身不足以产生临床表型,并且需要额外的修饰因子来使 m.7444 G>A 取代产生致病性表现。此外,我们描述了第一个波兰非综合征型听力损失家族,携带 m.7445 A>G 突变。当包括氨基糖苷类药物引起的听力损失时,该家系听力损失的外显率为 58%,当排除耳毒性作用时,外显率为 8%。这一发现强烈表明 m.7445 A>G 可能在氨基糖苷类诱导的听力损失易感性中起作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验